Ligand Pharmaceuticals Inc. has agreed to license one of its patented products for use in a Connecticut-based drugmaker’s intravenous medicine believed to helpful in controlling seizures and anxiety.

The San Diego-based pharmaceutical company announced April 5 it has struck a commercial license and supply agreement allowing Branford-based Marinus Pharmaceuticals Inc. to use Captisol, Ligand’s chemically modified cyclodextrin, in an IV form of ganaxolone.

Captisol is designed to optimize the solubility and stability of drugs.

Ganaxolone has shown promise in limiting seizures and anxiety through its effects on receptors in the human nervous system.

Marinus hopes to begin clinical trials on Captisol-enabled ganaxolone IV in patients suffering from postpartum depression and status epilepticus.

The new agreement replaces an earlier accord that allowed Marinus to evaluate the same combination of products in preclinical and Phase 1 clinical studies.

Ligand said that under the deal, it is entitled to potential milestone payments from Marinus, as well as royalties and other revenue from future sales of Captisol-enabled ganaxolone.